louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05707923: How Simplified Language Affects Comprehension and Learning in Young Autistic Children
Official title: How Single-Word and Telegraphic Simplification Affects Language Processing and Word Learning in Young Children With Autism Spectrum Disorder
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Autism Spectrum Disorder
Keywords: language
autism
intervention
processing
learning
early childhood
treatment
early intervention
telegraphic
language input
looking-while-listening
eye tracking
comprehension
neurodevelopmental disorders
Lead sponsor: Michigan State University
Sponsor class: OTHER
Collaborators: name: National Institute on Deafness and Other Communication Disorders (NIDCD)
First posted: 2023-02-01
Enrollment: 104
Sex: ALL
Minimum age (years): 1
Maximum age (years): 4
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The long-term study goal is to experimentally evaluate the components (and likely active ingredients) of early language interventions for young children with ASD. The overall objective is to determine how single-word and telegraphic simplification affects real-time language processing and word learning in young children with ASD (relative to full, grammatical utterances). The proposed project will investigate three specific aims: 1) Determine how single-word and telegraphic simplification affects language processing. 2) Determine how single-word and telegraphic simplification affects word learning. 3) Evaluate child characteristics that may moderate the effects of linguistic simplification on language processing and word learning. Aim 1 will test the hypothesis that children with ASD will process full, grammatical utterances faster and more accurately than single-word or telegraphic utterances. Aim 2 will test the hypothesis that full, grammatical utterances will support word learning better than telegraphic or single-word utterances. Aim 3 will test the hypothesis that language and cognitive skills significantly moderate the effects of linguistic simplification on language processing and word learning in young children with ASD.


Eligibility criteria: Inclusion Criteria:

* Existing or suspected autism spectrum disorder, confirmed through ADOS-2
* English as primary language
* 1-4 years old

Exclusion Criteria:

* Known genetic condition (e.g., Down syndrome, fragile X)
* Cerebral palsy
* Acquired brain injury
* Uncorrected vision or hearing impairment

Primary outcomes:
measure: Gaze location on Looking-While-Listening (LWL) tasks
timeFrame: Single assessment per task; total duration less than 10 minutes per task
Secondary outcomes:
measure: Gaze location in Teaching Phase of Study 2b (Fast Mapping)
timeFrame: Single assessment; total duration less than 10 minutes
Other outcomes:
Locations:
city: East Lansing
country: United States
facility: Michigan State University
state: Michigan
Study officials:
References:
Clinical trial NCT03464123: Brain Oxygenation During Cardiopulmonary Resuscitation
Official title: Brain Oxygenation During Cardiopulmonary Resuscitation - Observational Pilot Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Cardiac Arrest, Out-Of-Hospital
Lead sponsor: Helsinki University Central Hospital
Sponsor class: OTHER
First posted: 2018-03-13
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All adult patients met in cardiac arrest by the physician-led prehospital critical care team are to be screened and recruited based the eligibility criteria. The patients include patients in all primary rhythms.

Brief summary: The study is aimed to assess (a) the incidence of hyperoxia at the point of return of spontaneous circulation (ROSC) and (b) the role of arterial blood oxygen partial pressure to brain oxygenation during out-of-hospital cardiac arrest. 80 adult patients will be recruited in a physician staffed helicopter emergency medical services. Brain regional oxygen saturation and invasive blood pressure are monitored until hospital admission and arterial blood gases are analyzed immediately when the unit arrives to the patient and again at the time of ROSC.


Eligibility criteria: Inclusion Criteria:

* out-of-hospital cardiac arrest of presumed cardiac origin
* resuscitation will be continued at least 5 minutes (if return of spontaneous circulation not achieved earlier) after arrival of physician team

Exclusion Criteria:

* do-not-attempt-resuscitation (DNAR) order or withdrawal of treatment by prehospital critical care physician
* return of spontaneous circulation achieved before physician-led critical team arrives
* external cause for cardiac arrest (e.g. trauma, suffocation)
* workload too high or environment too dangerous to perform study procedures

Primary outcomes:
measure: Arterial oxygen partial pressure
timeFrame: 5-60 minutes
Secondary outcomes:
measure: Forehead regional oxygen saturation during resuscitation
timeFrame: 0-60 minutes
Other outcomes:
Locations:
city: Vantaa
country: Finland
facility: FinnHEMS 10, Emergency Medicine and Services, Helsinki University Hospital
Study officials:
affiliation: Helsinki University Central Hospital
name: Jouni Nurmi, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00814723: Fluvastatin 80 mg Ret. vs Combination With Ezetimibe 10 mg in Patients With High Cardiovascular Risk
Official title: Fluvastatin 80 mg Ret. vs Combination With Ezetimibe 10 mg in Patients With High Cardiovascular Risk
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Hypercholesterolemia
Lead sponsor: Medical University of Graz
Sponsor class: OTHER
First posted: 2008-12-25
Enrollment: 90
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Patients with coronary heart disease (CHD) or CHD equivalent (e. g. diabetes mellitus) often have abnormalities in lipids (hypercholesterolemia). Besides, hypercholesterolemia is an evident risk factor for atherosclerosis. Hitherto, there are only few studies of patients with primary hypercholesterolemia where the combination therapy with statins (HMG-Co-reductase inhibitors) and ezetimib was investigated. This combination therapy should be more effective in reducing low density lipoprotein cholesterol (LDL-C) and total cholesterol levels compared to monotherapy.

Detailed description: Ezetimibe, a cholesterol-absorption inhibitor, significantly lowers low-density lipoprotein cholesterol (LDL-C) when administered in addition to statin treatment. The effect of ezetimibe on the incidence and progression of vascular disease is elusive. Therefore, our objective was to examine the effects of fluvastatin and fluvastatin plus ezetimibe on lipoprotein subfractions in patients with diabetes mellitus and/or coronary heart disease.

Eligibility criteria: Inclusion Criteria:

* Patients with CHD or CHD equivalent with LDL 100-160 mg/dl
* Male or female sex
* Normal values of CK, AST and ALT
* Normal kidney function

Exclusion Criteria:

* CHD Stage III-IV
* St. p. myocardial infarction or coronary artery bypass grafting
* Pregnancy or breastfeeding
* Premenopausal women without certain contraception
* Known hypersensitivity to HMG-CoA reductase inhibitors or ezetimib

Primary outcomes:
measure: Reduction in Low density lipoprotein cholesterol (LDL-C)
timeFrame: week 6 and 12
Secondary outcomes:
measure: Total cholesterol, triglycerides, HDL-C, lipoprotein subfractions, hs-CRP
timeFrame: week 6 and 12
measure: adverse events, CK elevation, liver enzyme elevation
timeFrame: week 6, 12
Other outcomes:
Locations:
city: Graz
country: Austria
facility: Depart. of Internal Medicine, Medical University of Graz
Study officials:
affiliation: Medical University of Graz, Synlab Medizinisches Versorgungszentrum für Labordiagnostik Heidelberg
name: Winfried März, Prof., M.D.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Stojakovic T, de Campo A, Scharnagl H, Sourij H, Schmolzer I, Wascher TC, Marz W. Differential effects of fluvastatin alone or in combination with ezetimibe on lipoprotein subfractions in patients at high risk of coronary events. Eur J Clin Invest. 2010 Mar;40(3):187-94. doi: 10.1111/j.1365-2362.2009.02249.x. Epub 2010 Jan 7.
Clinical trial NCT03930823: Interviews With Older People From Turkish Origin in Belgium About Advance Care Planning
Official title: Advance Care Planning Among Older People From Turkish Origin in Belgium: An Exploratory Interview Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Advance Care Planning
Ethnic Minorities
Turkish Origin
Advance Medical Directives
Muslims
Living Will
Lead sponsor: Universitair Ziekenhuis Brussel
Sponsor class: OTHER
First posted: 2019-04-29
Enrollment: 51
Sex: ALL
Minimum age (years): 65
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: One to one Interviews
Primary purpose: OTHER

Brief summary: Advance care planning (ACP) enables individuals to define goals and preferences for future medical treatment and care, to discuss these goals and preferences with family and health-care providers, and to record and review these preferences if appropriate. Research has shown that most Western patients express the need about what ACP entails.

Ethnicity creates an important cultural impact on how people look at life and death, so that there is an influence on making decisions about end-of-life care. The Turkish ethnic group is one of the largest visible non-Western minority groups in Western countries. Studies on how ACP is perceived among patients from Turkish origin are lacking.

The objective of this study is exploring the knowledge, experiences, point of views, preferences, attitudes, facilitators and barriers concerning advance care planning of older people from Turkish origin in Belgium. Semi-structured interviews (in the native Turkish language) will be used.


Eligibility criteria: Inclusion Criteria:

People:

* with Turkish origin who live in Belgium and are older than 65 years
* who have also given informed consent to participate in this qualitative interview study

Exclusion Criteria:

* Patients who are terminal ill which means having a life-limiting disease with irreversible decline and who are actively dying (actively dying is related to patients with days of survival). (41)
* Having cognitive impairment

Primary outcomes:
measure: Knowledge about advance care planning from older people from Turkish origin in Belgium
timeFrame: 9 months
measure: Experiences about advance care planning from older people from Turkish origin in Belgium
timeFrame: 9 months
measure: Views/preferences about advance care planning from older people from Turkish origin in Belgium
timeFrame: 9 months
measure: Attitudes about advance care planning from older people from Turkish origin in Belgium
timeFrame: 9 months
measure: Barriers and facilitators for advance care planning from older people from Turkish origin in Belgium
timeFrame: 9 months
Secondary outcomes:
Other outcomes:
Locations:
city: Brussels
country: Belgium
facility: Faculteit Geneeskunde en Farmacie
Study officials:
affiliation: Vrije Universiteit Brussel
name: Hakki Demirkapu, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01622023: Timing of Intrauterine Insemination (IUI) 24 or 48 Hours After Spontaneous Luteinizing Hormone (LH) Peak
Official title: Timing of IUI 24 or 48 Hours After Spontaneous LH Peak: a Randomised Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Pregnancy
Keywords: insemination
donor sperm
natural cycle
Lead sponsor: Universitair Ziekenhuis Brussel
Sponsor class: OTHER
First posted: 2012-06-18
Enrollment: 435
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 39
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of the present study is to prospectively evaluate whether performing an intra-uterine insemination 24 hours after the spontaneous LH peak may result in significantly higher ongoing pregnancy rates compared to 48 hours.


Eligibility criteria: Inclusion Criteria:

* below 39 years of age on the day of LH peak
* donor semen
* natural cycle (without CC)
* cycle with less than 3 follicles reaching 15 mm of diameter or more.
* with basal hormonal values of progesterone ( \< 1,2 ng/dl)

Exclusion Criteria:

The patients excluded are women

* who underwent more than 6 intrauterine inseminations,
* with tubal infertility

Primary outcomes:
measure: pregnancy rate
timeFrame: end of 2013 (up to 2 years)
Secondary outcomes:
measure: live birth rate
timeFrame: end of 2013 (up to 2 years)
Other outcomes:
Locations:
city: Brussel
country: Belgium
facility: Christophe Blockeel
Study officials:
References:
citation: Blockeel C, Knez J, Polyzos NP, De Vos M, Camus M, Tournaye H. Should an intrauterine insemination with donor semen be performed 1 or 2 days after the spontaneous LH rise? A prospective RCT. Hum Reprod. 2014 Apr;29(4):697-703. doi: 10.1093/humrep/deu022. Epub 2014 Feb 18.
Clinical trial NCT01993823: Clinical Study to Assess the Efficacy and Safety of G238 Compared to Clotrimazole Otic Solution in the Treatment of Otomycosis
Official title: A Phase III, Multicenter, Randomized, Double-blind, Parallel Group, Active Treatment-controlled Study Assessing the Safety and Efficacy of G238 Compared to Clotrimazole 1% Otic Solution in Patients With Otomycosis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Otomycosis
Lead sponsor: Salvat
Sponsor class: INDUSTRY
First posted: 2013-11-25
Enrollment: 190
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the safety and efficacy of G238 for the treatment of otomycosis


Eligibility criteria: Inclusion Criteria:

* 18 years or older.
* Clinical diagnosis of otomycosis where topical treatment is indicated.

Exclusion Criteria:

* Other ear diseases.

Primary outcomes:
measure: Proportion of Subjects With a Complete Response to Treatment
timeFrame: Day 24
Secondary outcomes:
measure: Changes in Signs/ Symptoms
timeFrame: 2 weeks and 4 weeks
Other outcomes:
measure: Mycological Study
timeFrame: Day 24
Locations:
city: Esplugues de Llobregat
country: Spain
facility: Laboratorios SALVAT, S.A.
state: Barcelona
Study officials:
References:
citation: Lee A, Tysome JR, Saeed SR. Topical azole treatments for otomycosis. Cochrane Database Syst Rev. 2021 May 25;5(5):CD009289. doi: 10.1002/14651858.CD009289.pub2.
Clinical trial NCT06455423: Supplemental Effects of ELDOA in Addition to Thoracic Manipulation on Upper Back Pain, Thoracic Kyphosis and Forward Head Posture in Thoracic Hypomobility
Official title: Supplemental Effects of ELDOA in Addition to Thoracic Manipulation on Upper Back Pain, Thoracic Kyphosis and Forward Head Posture in Thoracic Hypomobility (The ELDOA-MAN Study)
Study type: INTERVENTIONAL
Overall status: ENROLLING_BY_INVITATION
Phase: NA
Conditions: Forward Head Posture
Thoracic Hypomobility
Upper Back Pain
Lead sponsor: Foundation University Islamabad
Sponsor class: OTHER
First posted: 2024-06-12
Enrollment: 40
Sex: ALL
Minimum age (years): 19
Maximum age (years): 44
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: The study will consist of two groups.
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine the supplemental effects of ELDOA in addition to thoracic manipulation on upper back pain, thoracic kyphosis and forward head posture in thoracic hypomobility.


Eligibility criteria: Inclusion Criteria:

* Both male and females
* Adults (19-44 years)
* Upper back pain or discomfort
* Forward head posture
* Thoracic hypomobility
* Thoracic hyperkyphosis

Exclusion Criteria:

* Ankylosing spondylitis
* History of Spinal Fusion or spinal surgery (discectomy/laminectomy etc.)
* Degenerative disc disorders, Facet joint syndrome
* Cervical radiculopathy, Scoliosis
* Spinal Stenosis or Myelopathy
* Recent fracture or surgery
* TB of spine, Spondylolisthesis
* Not able to attend regular therapy appointments
* Fibromyalgia/myofascial pain syndrome

Primary outcomes:
measure: Upper Back Pain or Discomfort
timeFrame: 3 weeks
measure: Thoracic Kyphosis
timeFrame: 3 weeks
measure: Thoracic Range of Motion (ROM)
timeFrame: 3 weeks
measure: Forward Head Posture
timeFrame: 3 weeks
measure: Functional ability
timeFrame: 3 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Islamabad
country: Pakistan
facility: Foundation University Islamabad
state: Federal
Study officials:
affiliation: Foundation University Islamabad
name: Samra Batool
role: PRINCIPAL_INVESTIGATOR
affiliation: Foundation University Islamabad
name: Muhammad Osama
role: STUDY_CHAIR
References:
Clinical trial NCT02275923: Reveal LINQ™ Evaluation of Fluid
Official title: Reveal LINQ™ Evaluation of Fluid
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: End Stage Renal Disease
Lead sponsor: Medtronic Cardiac Rhythm and Heart Failure
Sponsor class: INDUSTRY
First posted: 2014-10-27
Enrollment: 9
Sex: ALL
Minimum age (years): 21
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The purpose of this study is to investigate the use of subcutaneous impedance measured with an implanted Medtronic Reveal LINQ™ insertable cardiac monitor for use as a fluid status monitor in hemodialysis patients. The study will measure the changes in subject subcutaneous impedance and compare with the fluid status assessed by the volume removed from the hemodialysis subject during dialysis sessions. Subcutaneous impedance trends will also be evaluated between dialysis sessions.


Eligibility criteria: Inclusion Criteria:

* Patients who currently undergo in-clinic hemodialysis treatment prescribed 2 or 3 times per week
* Patients willing to be implanted with the Reveal LINQ™ device
* Patients greater than 21 years of age
* Patients willing and able to comply with the study procedures including giving informed consent

Exclusion Criteria:

* Patient has an active implanted cardiac medical device (e.g. IPG, ICD, CRT, etc)
* Patients who currently undergo home dialysis treatment
* Patient is enrolled in another study that could confound the results of this study, without documented pre-approval from a Medtronic study manager.
* Patient with a recent infection defined as 1) bacteremia within 60 days OR 2) (nonbacteremic) infection within 14 days
* Patient not suitable for Reveal LINQ™ implantation (e.g., severe cachexia, dermatologic conditions of the skin, or major medical or social conditions expected to reduce survival to \< 6 months), in the opinion of the investigator

Primary outcomes:
measure: Average Fluid Volume Removed
timeFrame: 24 Days
measure: Change in Subcutaneous Impedance
timeFrame: 24 days
Secondary outcomes:
Other outcomes:
Locations:
city: Melbourne
country: Australia
facility: The Alfred Hospital
state: Victoria
Study officials:
References:
Clinical trial NCT00647023: Incretin Secretion in Women With Polycystic Ovary Syndrome (PCOS)
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Polycystic Ovary Syndrome
Lead sponsor: Hvidovre University Hospital
Sponsor class: OTHER
Collaborators: name: University of Copenhagen
First posted: 2008-03-31
Enrollment: 66
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 38
Standard ages: ADULT
Accepts healthy volunteers: yes
Primary purpose: BASIC_SCIENCE

Brief summary: The incretin hormones are secreted from the gastrointestinal tract in response to nutrient ingestion, and are responsible for 70 % of insulin secretion in response to glucose. The incretin response is attenuated in subjects with type 2 diabetes and other conditions associated with insulin resistance. Polycystic ovary syndrome (PCOS) is characterised by irregular periods and increased androgen levels. It is the most common endocrine disorder amongst young women at fertile age, and the most common cause of female infertility. Insulin resistance plays an important role in the development of the disease, and women with PCOS are at increased risk of developing tyoe 2 diabetes. the incretin hormones have not previously been investigated in women with PCOS, and the purpose of the present study was to investigate the secretion of the two most important incretin hormones Glucose-like peptide-1 (GLP-1) and Glucose dependent insulinotropic peptide (GIP) during a three hour oral glucose tolerance test.


Eligibility criteria: Inclusion Criteria:

* Subjects who fulfill the Rotterdam criteria for PCOS. Age 18-38

Exclusion Criteria:

* Other endocrine diseases or diseases known to influence glucose/insulin/fat metabolism
* Oral contraceptive administration within three months of study start

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References: